Key Points
- Insider sale: Edwards Lifesciences VP Daniel Lippis sold 619 shares at an average price of $87.51, totaling $54,168.69. The transaction was made under a pre-arranged Rule 10b5-1 plan, leaving him with 40,034 shares.
- Financial performance: The company’s latest quarterly results exceeded expectations, with EPS of $0.78 versus the $0.74 consensus and revenue of $1.74 billion, up 13.6% year over year.
- Analyst outlook: Edwards has a “Moderate Buy” consensus rating from analysts, with an average price target of $100.27 versus a recent share price of $84.54. Expanded Medicare coverage for certain TAVR patients could support future demand, although the stock’s valuation near 49 times earnings may increase its sensitivity to market weakness.
Edwards Lifesciences Corporation (NYSE:EW - Get Free Report) VP Daniel Lippis sold 619 shares of the firm's stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $87.51, for a total value of $54,168.69. Following the completion of the sale, the vice president directly owned 40,034 shares of the company's stock, valued at $3,503,375.34. This represents a 1.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Edwards Lifesciences Stock Down 2.6%
Edwards Lifesciences stock opened at $84.54 on Friday. The stock's 50 day moving average price is $89.16 and its 200 day moving average price is $85.79. Edwards Lifesciences Corporation has a 1-year low of $72.30 and a 1-year high of $96.29. The company has a market cap of $48.68 billion, a PE ratio of 48.59, a price-to-earnings-growth ratio of 2.28 and a beta of 0.85. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77.
Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The firm had revenue of $1.74 billion during the quarter, compared to analysts' expectations of $1.70 billion. During the same quarter in the prior year, the business posted $0.67 earnings per share. Edwards Lifesciences's revenue was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, sell-side analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.
Analysts Set New Price Targets
EW has been the subject of several recent analyst reports. Weiss Ratings reiterated a "hold (c)" rating on shares of Edwards Lifesciences in a research note on Friday, July 17th. UBS Group began coverage on shares of Edwards Lifesciences in a research report on Tuesday, July 28th. They set a "buy" rating and a $110.00 target price on the stock. Citigroup increased their target price on shares of Edwards Lifesciences from $101.00 to $110.00 and gave the company a "buy" rating in a report on Wednesday, July 8th. Evercore reaffirmed an "outperform" rating and issued a $100.00 target price on shares of Edwards Lifesciences in a report on Monday, July 6th. Finally, Mizuho lifted their price target on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the company an "outperform" rating in a research report on Wednesday, July 15th. Seventeen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $100.27.
Get Our Latest Stock Analysis on EW
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the company. Hanson & Doremus Investment Management acquired a new stake in Edwards Lifesciences in the 1st quarter valued at about $25,000. JPL Wealth Management LLC acquired a new position in Edwards Lifesciences during the third quarter worth about $25,000. MV Capital Management Inc. acquired a new position in Edwards Lifesciences during the fourth quarter worth about $26,000. RMG Wealth Management LLC purchased a new stake in shares of Edwards Lifesciences in the first quarter valued at about $26,000. Finally, Pin Oak Investment Advisors Inc. purchased a new stake in shares of Edwards Lifesciences in the second quarter valued at about $26,000. Hedge funds and other institutional investors own 79.46% of the company's stock.
Key Edwards Lifesciences News
Here are the key news stories impacting Edwards Lifesciences this week:
- Positive Sentiment: CMS expands TAVR coverage: The Centers for Medicare and Medicaid Services will extend Medicare coverage to certain patients with severe aortic stenosis who do not yet have symptoms. The broader eligible patient population could increase demand for Edwards’ TAVR valves and procedures, a particularly important growth opportunity for the company. CMS expands TAVR Medicare coverage to asymptomatic patients
- Positive Sentiment: Company welcomes the policy: Edwards said the national coverage determination should improve patient access to TAVR while reinforcing the role of multidisciplinary Heart Teams. The company also reaffirmed its 2026 financial guidance following the decision, suggesting no immediate deterioration in its outlook. Edwards Lifesciences Reaffirms 2026 Guidance Following Medicare TAVR Decision
- Positive Sentiment: Analysts remain bullish: Citi initiated or reiterated a Buy view, while BTIG reaffirmed its Buy rating with a $110 price target. William Blair also maintained a Buy rating, citing the expanded TAVR coverage and inclusion of asymptomatic patients. These targets imply substantial potential upside from recent trading levels. Analyst Buy Rating on Edwards Lifesciences
- Neutral Sentiment: Why the stock may still be under pressure: The reports identify no new company-specific negative catalyst. Investors may be waiting for evidence that the CMS change translates into procedure volumes and revenue, while Edwards’ relatively elevated valuation—about 49 times earnings—could make the shares sensitive to profit-taking or broader market weakness.
Edwards Lifesciences Company Profile
(
Get Free Report)
Edwards Lifesciences Corporation (NYSE:EW) is a medical technology company focused on therapies for structural heart disease. Its products are designed to treat conditions affecting the heart valves and related cardiovascular structures, helping patients with diseases such as aortic stenosis, mitral regurgitation and tricuspid valve disorders.
The company's portfolio includes transcatheter aortic valve replacement systems, including its SAPIEN platform, as well as transcatheter mitral and tricuspid therapies and surgical heart valve products.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
